| 4.61 0 (0%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.81 | 1-year : | 6.71 |
| Resists | First : | 4.97 | Second : | 5.74 |
| Pivot price | 4.69 |
|||
| Supports | First : | 3.73 | Second : | 3.1 |
| MAs | MA(5) : | 4.87 |
MA(20) : | 4.62  |
| MA(100) : | 4.38 |
MA(250) : | 4.37 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 46.4 |
D(3) : | 55 |
| RSI | RSI(14): 51.1 | |||
| 52-week | High : | 7.11 | Low : | 3.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCEL ] has closed above bottom band by 44.6%. Bollinger Bands are 37.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.69 - 4.72 | 4.72 - 4.75 |
| Low: | 4.39 - 4.42 | 4.42 - 4.45 |
| Close: | 4.56 - 4.61 | 4.61 - 4.65 |
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Sun, 26 Jul 2026
AVITA Medical Inc (RCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sun, 26 Jul 2026
AVITA Medical Inc (RCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sat, 25 Jul 2026
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Sat, 25 Jul 2026
Avita Medical (NASDAQ:RCEL) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Tue, 21 Jul 2026
RCEL stock trades near recent highs as Avita Medical revenue accelerates - AD HOC NEWS
Thu, 09 Jul 2026
12 Health Care Stocks Moving In Thursday's After-Market Session - AVITA Medical (NASDAQ:RCEL), Lisata The - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 31 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 2,530 (K) |
| Shares Short P.Month | 3,300 (K) |
| EPS | -1.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.75 |
| Profit Margin | -62.7 % |
| Operating Margin | -45.8 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 2.35 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.96 |
| PEG Ratio | 0 |
| Price to Book value | -6.15 |
| Price to Sales | 1.96 |
| Price to Cash Flow | -4.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|